|
Name |
Sartorypyrone A
|
Molecular Formula | C28H40O5 | |
IUPAC Name* |
[(1S,3R)-3-[(3E,7E)-9-(4-hydroxy-6-methyl-2-oxopyran-3-yl)-3,7-dimethylnona-3,7-dienyl]-2,2-dimethyl-4-methylidenecyclohexyl] acetate
|
|
SMILES |
CC1=CC(=C(C(=O)O1)C/C=C(\C)/CC/C=C(\C)/CC[C@@H]2C(=C)CC[C@@H](C2(C)C)OC(=O)C)O
|
|
InChI |
InChI=1S/C28H40O5/c1-18(11-14-23-25(30)17-21(4)32-27(23)31)9-8-10-19(2)12-15-24-20(3)13-16-26(28(24,6)7)33-22(5)29/h10-11,17,24,26,30H,3,8-9,12-16H2,1-2,4-7H3/b18-11+,19-10+/t24-,26+/m1/s1
|
|
InChIKey |
VDURTFXVMLMCFA-GISJPLNESA-N
|
|
Synonyms |
Sartorypyrone A; 1452396-10-9; [(1S,3R)-3-[(3E,7E)-9-(4-hydroxy-6-methyl-2-oxopyran-3-yl)-3,7-dimethylnona-3,7-dienyl]-2,2-dimethyl-4-methylidenecyclohexyl] acetate; rel-(+)-3-[(2E,6E)-9-[(1R,3S)-3-(acetyloxy)-2,2-dimethyl-6-methylenecyclohexyl]-3,7-dimethyl-2,6-nonadien-1-yl]-4-hydroxy-6-methyl-2H-pyran-2-one
|
|
CAS | NA | |
PubChem CID | 72547199 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 456.6 | ALogp: | 6.8 |
HBD: | 1 | HBA: | 5 |
Rotatable Bonds: | 10 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 72.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 33 | QED Weighted: | 0.338 |
Caco-2 Permeability: | -4.794 | MDCK Permeability: | 0.00003280 |
Pgp-inhibitor: | 0.969 | Pgp-substrate: | 0.03 |
Human Intestinal Absorption (HIA): | 0.013 | 20% Bioavailability (F20%): | 0.771 |
30% Bioavailability (F30%): | 0.004 |
Blood-Brain-Barrier Penetration (BBB): | 0.223 | Plasma Protein Binding (PPB): | 95.30% |
Volume Distribution (VD): | 0.172 | Fu: | 1.93% |
CYP1A2-inhibitor: | 0.13 | CYP1A2-substrate: | 0.133 |
CYP2C19-inhibitor: | 0.445 | CYP2C19-substrate: | 0.131 |
CYP2C9-inhibitor: | 0.732 | CYP2C9-substrate: | 0.976 |
CYP2D6-inhibitor: | 0.309 | CYP2D6-substrate: | 0.899 |
CYP3A4-inhibitor: | 0.624 | CYP3A4-substrate: | 0.279 |
Clearance (CL): | 2.762 | Half-life (T1/2): | 0.195 |
hERG Blockers: | 0.004 | Human Hepatotoxicity (H-HT): | 0.648 |
Drug-inuced Liver Injury (DILI): | 0.492 | AMES Toxicity: | 0.005 |
Rat Oral Acute Toxicity: | 0.004 | Maximum Recommended Daily Dose: | 0.96 |
Skin Sensitization: | 0.654 | Carcinogencity: | 0.017 |
Eye Corrosion: | 0.005 | Eye Irritation: | 0.055 |
Respiratory Toxicity: | 0.592 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004068 | 0.496 | D03VFL | 0.347 | ||||
ENC006119 | 0.390 | D09XWD | 0.273 | ||||
ENC003133 | 0.344 | D04FBR | 0.266 | ||||
ENC005337 | 0.331 | D05XQE | 0.252 | ||||
ENC003797 | 0.331 | D0L7AS | 0.244 | ||||
ENC003495 | 0.327 | D0Q0PR | 0.238 | ||||
ENC005341 | 0.325 | D0X7XG | 0.237 | ||||
ENC005338 | 0.325 | D0P1FO | 0.234 | ||||
ENC001464 | 0.321 | D0H2MO | 0.219 | ||||
ENC005339 | 0.321 | D0O1UZ | 0.216 |